
Sign up to save your podcasts
Or
Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
5
1515 ratings
Todd Carter, PhD (CSO at Voyager Therapeutics) talks with incoming Communications Committee Chair Lynnea Olivarez about changes in the approach to developing gene therapies for CNS disorders like Huntington's disease.
Show your support for ASGCT!: https://asgct.org/membership/donate
See omnystudio.com/listener for privacy information.
6,244 Listeners
760 Listeners
817 Listeners
37,887 Listeners
2,053 Listeners
322 Listeners
122 Listeners
268 Listeners
9,516 Listeners
317 Listeners
6,233 Listeners
30 Listeners
144 Listeners
17 Listeners
39 Listeners